Tractor Supply (TSCO) Seen as “Hedge” Against Consumer Uncertainty, According to Jefferies
Yahoo Finance· 2025-12-02 21:05
Tractor Supply Company (NASDAQ:TSCO) is included among the 15 High Quality Dividend Stocks for Long-Term Investors. Tractor Supply (TSCO) Seen as “Hedge” Against Consumer Uncertainty, According to Jefferies Photo by Annie Spratt on Unsplash On November 24, Jefferies analyst Jonathan Matuszewski upgraded Tractor Supply Company (NASDAQ:TSCO) to Buy from Hold, raising the price target to $64 from $58. The analyst noted that the shares could serve as a “hedge” to the ongoing consumer uncertainty ...
炼化反内卷 行业加速头部化
21世纪经济报道· 2025-12-02 21:05
(原标题:炼化反内卷 行业加速头部化) 历经四年之久行业承压,炼化行业的反转因子,几乎在2025年下半年形成完美共振。 2022年以来,全球整体经济环境低迷,总体需求遭到冲击;加之各国环保减碳措施不断出台,新材料形 成部分替代效应,行业整体进入存量博弈阶段。 行业公开信息显示,11月底,我国2026年原油进口配额提前批下发。其中恒力石化旗下大连恒力、荣盛 石化、东方盛虹旗下盛虹炼化分别获得300万吨、75万吨和50+万吨的配额。 值得注意的是,相比2025年第一批获得配额的数十家山东、河南"地炼"企业,2026年"提前批"仅三家头 部民营大炼化获得配额——而以上企业均有较强的一体化装置与产业协同优势,为明确的"先进产能"。 考虑到以上企业在2026年均有主要在建产能落地,配额"厚此薄彼"的背后,由政策力量主导的行业出 清,以产业头部化为路径的"反内卷"模式,已跃然纸上。 事实上,今年下半年以来,工信部、行业协会、头部企业陆续出台的政策、行业自律措施等,加速促进 炼化行业形成反内卷的趋势。 当所有行业积极因素堆积共振,2026年,炼化行业的曙光是否就在眼前? 反内卷政策集中出台 今年10月29日,工信部原材料工 ...
Fulgent Genetics: From Genetic Code To Cancer Cure - Why I Assign A Hold Rating (NASDAQ:FLGT)
Seeking Alpha· 2025-12-02 21:05
Fulgent Genetics, Inc. ( FLGT ) stock is trading at its 52-week highs after a solid double-digit gain over the past month. This significant growth followed its release of exciting Q3 numbers earlier in November, which saw hugeGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has ...
Oppenheimer Sees Dover (DOV) Well-Positioned for Earnings and Cash Flow Growth
Yahoo Finance· 2025-12-02 21:05
Dover Corporation (NYSE:DOV) is included among the 15 High Quality Dividend Stocks for Long-Term Investors. Oppenheimer Sees Dover (DOV) Well-Positioned for Earnings and Cash Flow Growth Photo by Dan Dennis on Unsplash On November 14, Oppenheimer raised its price target on Dover Corporation (NYSE:DOV) to $228 from $225 while maintaining an Outperform rating following an investor meeting with VP of IR Jack Dickens. During the session, questions focused on the company’s near-term positi ...
One State Erased $6.5 Billion in Debt for Millions — Can Your State Do It Too?
Yahoo Finance· 2025-12-02 21:05
North Carolina has achieved a milestone in medical debt resolution that patients across the country may be wishing would happen in their states. According to The Carolina Journal, more than $6.5 billion in medical debt has been eliminated for more than 2.5 million North Carolinians in the past year. Read More: 4 Retirement Expenses Boomers Didn’t Plan For — but Should Have Find Out: 9 Low-Effort Ways To Make Passive Income (You Can Start This Week) The state’s Medical Debt Relief Program was started in Ju ...
11月份汇丰晋信旗下12只基金跌超8%?均由陆彬管理
中国经济网· 2025-12-02 21:05
跌超9%的还有汇丰晋信核心成长混合C、汇丰晋信核心成长混合A,在11月也下跌了9.87%和 9.83%。这只成立于2021年5月24日的基金同样在陆彬4年多的管理下依然出现亏损,其最新累计收益率 分别为-8.76%、-6.67%。 其余几只基金的单月跌幅均在8%以上,其中,汇丰晋信时代先锋混合成立于2022年6月8日,截至 2025年12月1日其A/C份额的累计收益率跌幅分别为12.13%和13.90%,单位净值仅为0.8787元和0.8610 元。 中国经济网北京12月2日讯 据同花顺iFinD数据显示,2025年11月份,汇丰晋信基金公司旗下共有 12只基金(各份额分开计算,下同)跌幅超过8%,而这些基金全部由陆彬管理。 汇丰晋信研究精选混合跌幅最大,11月份下跌9.97%。资料显示,该基金成立于2022年1月21日, 一直由陆彬单独管理,但截至今年12月1日收盘,其累计收益率依然亏损3.23%。 从2025年前三个季度的重仓股看,其投资方向主要以新能源产业为主,其中又多集中在光伏领域。 三季报显示,前十大重仓股为亿纬锂能、晶澳科技、信义光能、通威股份、协鑫科技、隆基绿能、爱旭 股份、福莱特、杭可科技、明 ...
BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025
Globenewswire· 2025-12-02 21:05
MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for third quarter ended September 30, 2025 after the market close on Tuesday, December 9, 2025. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. To partic ...
BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization
Globenewswire· 2025-12-02 21:05
SHERIDAN, Wyo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a $500,000,000 Equity Purchase Agreement (the “Facility”) with ARC Group International Ltd. (“ARC”), a global investment bank and the parent of ARC Group Securities, a FINRA registered broker dealer. The Company believes this facility will provide it with long-term, disc ...
SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
Globenewswire· 2025-12-02 21:05
COMMACK, NY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that management will be participating in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th - 10t ...
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Businesswire· 2025-12-02 21:05
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the European Patent Office (EPO) has issued patent No. 4 496 611 titled, "Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.†The patent is jointly held by Savara and PARI and covers the combination of Savara's investigational therapy, MOLBREEVI, and PARI's investigationa. ...